Medrobotics Closes $11.7M Series C

Boston-based Medrobotics Corp. raised $11.7 million in Series C round to further its flexible medical robot technology. The company’s technology is designed to “enable surgeons to access, visualize and perform two-handed surgery in hard-to-reach anatomical places through a single-site access,” the company says. The Pittsburgh Life Sciences Greenhouse contributed to the round, as did other, undisclosed investors.

Boston-based, robotic snake technology developer, Medrobotics Corporation, announced today that it has closed “Series C” funding in the amount of $11.7 Million. The investment came from current shareholders, a number of new angel investors and from The Pittsburgh Life Sciences Greenhouse. In total, Medrobotics Corporation has raised $28.3 million in preferred equity financing since its academic founders spun it out from Carnegie Mellon University.

About Medrobotics Corporation
Medrobotics has developed a platform of flexible medical robots that enable surgeons to access, visualize, and perform two-handed surgery in hard-to-reach anatomical places through a single-site access. The core technology is a new generation of flexible robotic snakes with advanced vision systems that are able to navigate tortuous paths while providing accessory channels for a wide range of flexible surgical tools. The robots are self-supporting, which means they are able to support their own weight and move within any three-dimensional space without the need for any other structural support.

The Company maintains its corporate headquarters in the Boston area and plans to file for US commercial approval in 2012.

Find new deal opportunities, super-charge your fundraising efforts and track top managers with VCJ. Get your FREE trial! Or subscribe now

Sign up to our Newsletter

Receive updates from our PE HUB Wire and Top Stories of the Week newsletters:

We will not send you spam, and we don't share your email address with 3rd parties.